ABBV News 53.75 06/24/2014 04:21:51 Abbvie Inc. Common Stock

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbvie Inc. Common Stock (ABBV) 53.75 $ABBV

Shire Rejects AbbVie's Offer, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 4:31PM CDT
Shares of Shire plc (SHPG) soared 16.3% after the company rejected an acquisition offer from AbbVie (ABBV).

Cost Controls vs. Curing Citizens: Fallout from the U.K.
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 23, 4:30PM CDT
Just like the protagonist in " Fortunately, Unfortunately " Gilead Sciences is experiencing a disproportionate amount of highs and lows. Fortunately, the big biotech released great phase 3 data out of Japan for an experimental hepatitis-c combo...

Is Shire's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Mon Jun 23, 4:30PM CDT
Shire  ( )   is one of the globe's biggest drug companies. It's a major player in ADHD and rare disease, and the company has been rumored as a takeover target by  Allergan , and recently  AbbVie  announced its third attempt to buy the...

Shots Fired in the Next Tax Fleeing Battle
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Jun 23, 4:15PM CDT
Perpetual takeover target Shire  is officially in play. Long rumored as a takeover candidate given its strong ADHD franchise, its orphan drug focus, and most importantly its low Irish tax rates, Shire has an actual suitor in big pharma AbbVie ....

Takeover target Shire promises strong growth
AP - Mon Jun 23, 10:44AM CDT
LONDON (AP) — Takeover target Shire on Monday highlighted its potential as a standalone drugmaker, offering investors a rosy projection of its earnings potential that it believes is not reflected in the acquisition proposal made by U.S.-based rival AbbVie.

AbbVie, Shire Give Bullish Guidance Amid Buyout Talk
at Investor's Business Daily - Mon Jun 23, 10:24AM CDT
Big pharma AbbVie (ABBV) raised its 2014 earnings guidance Monday, sending the company's stock up 1.5% in morning trading on the stock market. Meanwhile, AbbVie's buyout target Shire (SHPG) detailed its own bullish guidance in explaining to investors...

Stocks Lower In Early Trade; Buffalo Wild Wings Breaks Out
at Investor's Business Daily - Mon Jun 23, 9:34AM CDT
Stocks were narrowly lower early Monday, with gains from some better-than-expected economic data doing little to boost the market. The Nasdaq and the S&P 500 were down 0.1%. The Dow Jones industrial average was off 0.2%. Volume was tracking lower on...

Stock Market News for June 23, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 9:06AM CDT
Benchmarks closed Friday’s trading session with modest gains as optimism from Wednesday’s policy statement spilled over into a second successive day

Monday’s Top Biotech Stocks to Watch: Rockwell, AbbVie, Shire, Allergan, and Valeant
Leo Sun, The Motley Fool - Motley Fool - Mon Jun 23, 8:20AM CDT
Let's take a look at five stocks -- Rockwell Medical , AbbVie , Shire , Allergan , and Valeant Pharmaceuticals -- which could all loom large in health care headlines this Monday morning. FDA approves Rockwell Medical's Calcitriol ...

Why AbbVie (ABBV) Stock Is Higher This Morning
at The Street - Mon Jun 23, 7:46AM CDT
Shares of AbbVie (ABBV) are up in pre-market trade as the pharmaceuticals company raised the midpoint of its full-year 2014 earnings-per-share guidance.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
PR Newswire Europe - Mon Jun 23, 7:11AM CDT
- AbbVie Raises Outlook for 2014

Here's Why AbbVie Wants to Cozy Up With Shire
Todd Campbell, The Motley Fool - Motley Fool - Sun Jun 22, 8:40PM CDT
Shire's c-suite thinks the company's future is pretty bright. The company's board dismissed a $46 billion offer to be acquired by drug giant AbbVie in May, even though that offer represented a 23% premium to its pre-offer price. According to...

This Week in Biotech: A Double-Dose of Hot Potato
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 21, 11:32AM CDT
With the  SPDR S&P Biotech Index  up  52% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...

Growth Stocks Kick Into Gear In Latest IBD 50 Screen
at Investor's Business Daily - Fri Jun 20, 5:35PM CDT
Have you noticed? Growth stocks are back in favor as major stock indexes sit near highs. The IBD 50 has come back to life in recent weeks. Since its mid-April low, the index is up 12% compared with an 8% gain for the S&P 500. Solid price action by...

Why AbbVie Wants Shire
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Fri Jun 20, 5:00PM CDT
Shares in Irish orphan and ADHD drug maker  Shire Plc   shot up today on the news that  AbbVie  , faced with the oncoming patent loss for Humira and looking to lower its tax rate, made public a rejected $46.5 billion bid today. This was the third bid...

Business Highlights
By The Associated Press - AP - Fri Jun 20, 4:47PM CDT
___

Why CarMax, Shire, and BlackBerry Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Fri Jun 20, 4:15PM CDT
The week ends as it began -- on a positive note, with the broad-based S&P 500 rising for a sixth-straight session and claiming another all-time high close. With no economic data on the table today, investors used ongoing merger and...

ConocoPhillips and Owens are big market movers
AP - Fri Jun 20, 3:30PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:

Just a Regular Day of Record Highs, No Big Deal
at The Street - Fri Jun 20, 3:21PM CDT
The S&P 500 is making this look easy as it closes at another record high to end the week. Since Monday, the benchmark index is up 1.38%.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 310

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
icles